We are monitoring the impact of COVID-19 on Ophthalmology Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1043
Share on
Share on

Global Ophthalmology Therapeutics Market Size, Share, Trends, COVID-19 Growth Analysis Report – Segmented By Basis of Indication, End User and Region – Industry Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1043
Pages: 175

Ophthalmology Therapeutics Market Size (2021 to 2026)

The size of the global ophthalmology therapeutics market is forecasted to be worth USD 39.47 billion by 2026, from USD 27.62 billion in 2021. This market is projected to be growing at a CAGR of 7.4% during the forecast period.

Ophthalmology is a medicine and surgery branch that deals with diagnosing and treating eye disorders, using laser therapies and medications to perform the surgeries. As per the World Health Organization, 2019, it is estimated that 2.2 billion people were visually impaired, over 39 million people had lost their vision, approximately 188.5 million people were suffered from mild vision impairment, and above 217 million people have been experiencing moderate to severe vision impairment. Vision eye care has become a costly affair, with the consistent rise in the widespread ophthalmologic diseases worldwide with the increasing cost of treatment and rising need for ophthalmology.

MARKET DRIVERS:

The global ophthalmology therapeutics market is showcasing the evident potential in the mentioned forecasting period. Ophthalmology is the branch of medicine associated with the treatment of eye defects and diseases. With the recent advancements in genetics and stem cell biology, the mechanisms of many ophthalmic diseases are being revealed progressively.

The constant increase in the widespread of ophthalmic diseases and the rising need for cost-effective ophthalmic disease therapeutics drive the market growth of the ophthalmology therapeutics market during the forecast period. An increase in presbyopia, molecular degeneration, and diabetic retinopathy is considered the major driver of the market. The ophthalmic disease market is expected to increase the market due to the increase in the research & development activities and investment funding by the government and various private organizations to improve the healthcare infrastructure. The introduction of ophthalmic devices, advanced technologies, and people in the emerging countries are opting for ophthalmic surgeries to correct their eye-aligned problems are further expected to propel the market growth. 

The global market for ophthalmology therapeutics is further driven by the growing prevalence of vision impairment, which was estimated to be 147 million in 2010. It is estimated to reach 191 million in the world in 2020. Technological advancement in the field of medicine is also playing a significant role in the growth of the market. Increasing the geriatric population worldwide and the rise in disposable income are some of the other factors driving the market for the global ophthalmology therapeutics market.

MARKET RESTRAINTS:

However, a lack of awareness about the various diseases associated with ophthalmology is a major factor restraining the market's growth. Stringent regulatory frameworks and unclear reimbursement policies are also acting as hurdles for market growth. Lack of awareness in rural areas about the various ophthalmic disorders and lack of health insurance covering all types of IOLs and contact lenses are restraining the market growth. Vision care has become a costly affair; many people in all parts of the world cannot afford ophthalmic treatments. This is considered as the primary factor for declining the global ophthalmology therapeutics market growth.

Impact of COVID-19 on the global ophthalmology therapeutics market:

COVID-19 was announced as a pandemic and emergence of healthcare. Coronavirus is an infectious disease; to control the virus's spread, the government has imposed nationwide lockdown and a ban on flights. During the first half of the period, the ophthalmology therapeutic market had declined growth rate. Due to the lockdown, all the ophthalmic treatments had been postponed. Increasing age-related Macular degeneration and increasing diagnosing and treating eye disorders have created the market demand during the pandemic period. 

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2020 to 2026

Base Year

2020

Forecast Period

2021 to 2026

Segments Covered

By Basis of Indication, End User and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, APAC, Latin America, Middle East & Africa

Market Leaders Profiled

Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath, and Eye Gate Pharmaceuticals

 

This research report on the global ophthalmology therapeutics market has been segmented and sub-segmented based on the indication, end-user, and region.

Ophthalmology Therapeutics Market - By Basis of Indication:

  • Glaucoma
  • Dry Eye Syndrome
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Age-related Macular Degeneration
  • Macular Edema
  • Allergic Conjunctivitis

Based on indication, the Glaucoma segment is the largest indication segment accounting for a share of approximately 31%, followed by AMD with a share of 27%. Also, the retinal vein Occlusion segment held the largest market share in 2019. It dominated the market share owing to the increased prevalence of age-related molecular degeneration, and pipeline candidates working on VEGF inhibition principles are expected to drive the segmentation growth during the forecast period.

Ophthalmology Therapeutics Market - By End User:

  • Hospitals
  • Eye Clinics
  • Diagnostic Centres
  • Patients

Based on the end-user, the eye clinics and hospitals are leading the market during the forecast period. The increasing prevalence of eye-related problems and the rising need for cost-effective ophthalmic disease therapeutics drive market growth.

Ophthalmology Therapeutics Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • The Middle East and Africa

Geographically, North America played the dominating role in the global ophthalmology therapeutics market in 2019, followed by Europe. Asia-Pacific is estimated to be the fastest-growing region during the forecast period.

The North American market held the largest share of the global ophthalmology therapeutics market. The market is expected to be driven by increasing awareness among the people about the benefits of ophthalmic drugs, and technological advancements have been increased. Moreover, government measures and increased investments by the government to improve the healthcare infrastructure are propelling the market growth over the forecast period.

The European market witnessed the majority share after North America and held the second most dominated region in the global ophthalmology therapeutics market during the forecast period. Increasing investments by the government and advancing healthcare infrastructure facilities are propelling the market. 

Asia Pacific is anticipated to increase CAGR over the forecast period. The factors such as rising disposable income, improving economic scenario, and the large patient pool are fuelling the market demand. The increasing introduction of new product launches is boosting the market growth over these years. 

Middle East & Africa is expected to record the major share in the coming years. Increasing patient pool and rise in the prevalence of presbyopia are boosting the market growth in this region.

KEY MARKET PLAYERS:

Some of the most prominent companies leading the global ophthalmology therapeutics market profiled in the report are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath, and Eye Gate Pharmaceuticals.

RECENT MARKET HAPPENINGS:

  • On 21st December 2020, eye gate pharmaceuticals, including a clinical-stage company, are focused on developing products to treat the eye.  

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Indication                              

                                5.1.1 Glaucoma

                                5.1.2 Dry Eye Syndrome

                                5.1.3 Diabetic Retinopathy         

                                5.1.4 Retinal Vein Occlusion        

                                5.1.5 Age-Related Macular Degeneration (AMD)

                                5.1.6 Macular Edema    

                                5.1.7 Allergic Conjunctivitis         

                5.2 By End User               

                                5.2.1 Hospitals  

                                5.2.2 Eye Clinics

                                5.2.3 Diagnostic Centers              

                                5.2.4 Patients   

6. Geographical Analysis                                              

                6.1 North America                          

                                6.1.1 Introduction           

                                6.1.2 United States         

                                6.1.3 Canada     

                6.2 Europe                         

                                6.2.1 Introduction           

                                6.2.2 U.K             

                                6.2.3 Spain         

                                6.2.4 Germany 

                                6.2.5 Italy           

                                6.2.6 France      

                6.3 Asia-Pacific                 

                                6.3.1 Introduction           

                                6.3.2 China         

                                6.3.3 India          

                                6.3.4 Japan        

                                6.3.5 South Korea           

                                6.3.6 Australia  

                6.4 Latin America                            

                                6.4.1 Introduction           

                                6.4.2 Brazil         

                                6.4.3 Argentina

                                6.4.4 Mexico     

                6.5 Middle East & Africa               

                                6.5.1 Introduction           

                                6.5.2 Middle-East            

                                6.5.3 Africa        

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Allergan, Inc.                              

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Merck & Co Inc                         

                9.3 Pfizer                            

                9.4 Roche                           

                9.5 Novartis (Alcon)                       

                9.6 Valeant                        

                9.7 Regeneron                 

                9.8 Santen                         

                9.9 Bayer                            

                9.10 Senju                          

                9.11 Lpath                          

                9.12 Eye Gate Pharmaceuticals                 

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Global Ophthalmology Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  2. Global Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  3. Global Glaucoma Market, By Region, From 2021 to 2026 (USD Million)
  4. Global Dry Eye Syndrome Market, By Region, From 2021 to 2026 (USD Million)
  5. Global Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  6. Global Retinal Vein Occlusion Market, By Region, From 2021 to 2026 (USD Million)
  7. Global Age-Related Macular Degeneration (AMD) Market, By Region, From 2021 to 2026 (USD Million)
  8. Global Macular Edema Market, By Region, From 2021 to 2026 (USD Million)
  9. Global Allergic Conjunctivitis Market, By Region, From 2021 to 2026 (USD Million)
  10. Global Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  11. Global Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  12. Global Eye Clinics Market, By Region, From 2021 to 2026 (USD Million)
  13. Global Diagnostic Centers Market, By Region, From 2021 to 2026 (USD Million)
  14. Global Patients Market, By Region, From 2021 to 2026 (USD Million)
  15. North America Ophthalmology Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  16. North America Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  17. North America Glaucoma Market, By Region, From 2021 to 2026 (USD Million)
  18. North America Dry Eye Syndrome Market, By Region, From 2021 to 2026 (USD Million)
  19. North America Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  20. North America Retinal Vein Occlusion Market, By Region, From 2021 to 2026 (USD Million)
  21. North America Age-Related Macular Degeneration (AMD) Market, By Region, From 2021 to 2026 (USD Million)
  22. North America Macular Edema Market, By Region, From 2021 to 2026 (USD Million)
  23. North America Allergic Conjunctivitis Market, By Region, From 2021 to 2026 (USD Million)
  24. North America Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  25. North America Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  26. North America Eye Clinics Market, By Region, From 2021 to 2026 (USD Million)
  27. North America Diagnostic Centers Market, By Region, From 2021 to 2026 (USD Million)
  28. North America Patients Market, By Region, From 2021 to 2026 (USD Million)
  29. United States Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  30. United States Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  31. Canada Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  32. Canada Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  33. Europe Ophthalmology Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  34. Europe Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  35. Europe Glaucoma Market, By Region, From 2021 to 2026 (USD Million)
  36. Europe Dry Eye Syndrome Market, By Region, From 2021 to 2026 (USD Million)
  37. Europe Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  38. Europe Retinal Vein Occlusion Market, By Region, From 2021 to 2026 (USD Million)
  39. Europe Age-Related Macular Degeneration (AMD) Market, By Region, From 2021 to 2026 (USD Million)
  40. Europe Macular Edema Market, By Region, From 2021 to 2026 (USD Million)
  41. Europe Allergic Conjunctivitis Market, By Region, From 2021 to 2026 (USD Million)
  42. Europe Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  43. Europe Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  44. Europe Eye Clinics Market, By Region, From 2021 to 2026 (USD Million)
  45. Europe Diagnostic Centers Market, By Region, From 2021 to 2026 (USD Million)
  46. Europe Patients Market, By Region, From 2021 to 2026 (USD Million)
  47. U.K Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  48. U.K Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  49. Spain Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  50. Spain Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  51. Germany Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  52. Germany Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  53. Italy Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  54. Italy Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  55. France Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  56. France Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  57. Asia-Pacific Ophthalmology Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  58. Asia-Pacific Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  59. Asia-Pacific Glaucoma Market, By Region, From 2021 to 2026 (USD Million)
  60. Asia-Pacific Dry Eye Syndrome Market, By Region, From 2021 to 2026 (USD Million)
  61. Asia-Pacific Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  62. Asia-Pacific Retinal Vein Occlusion Market, By Region, From 2021 to 2026 (USD Million)
  63. Asia-Pacific Age-Related Macular Degeneration (AMD) Market, By Region, From 2021 to 2026 (USD Million)
  64. Asia-Pacific Macular Edema Market, By Region, From 2021 to 2026 (USD Million)
  65. Asia-Pacific Allergic Conjunctivitis Market, By Region, From 2021 to 2026 (USD Million)
  66. Asia-Pacific Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  67. Asia-Pacific Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  68. Asia-Pacific Eye Clinics Market, By Region, From 2021 to 2026 (USD Million)
  69. Asia-Pacific Diagnostic Centers Market, By Region, From 2021 to 2026 (USD Million)
  70. Asia-Pacific Patients Market, By Region, From 2021 to 2026 (USD Million)
  71. China Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  72. China Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  73. India Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  74. India Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  75. Japan Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  76. Japan Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  77. South Korea Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  78. South Korea Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  79. Australia Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  80. Australia Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  81. Latin America Ophthalmology Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  82. Latin America Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  83. Latin America Glaucoma Market, By Region, From 2021 to 2026 (USD Million)
  84. Latin America Dry Eye Syndrome Market, By Region, From 2021 to 2026 (USD Million)
  85. Latin America Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  86. Latin America Retinal Vein Occlusion Market, By Region, From 2021 to 2026 (USD Million)
  87. Latin America Age-Related Macular Degeneration (AMD) Market, By Region, From 2021 to 2026 (USD Million)
  88. Latin America Macular Edema Market, By Region, From 2021 to 2026 (USD Million)
  89. Latin America Allergic Conjunctivitis Market, By Region, From 2021 to 2026 (USD Million)
  90. Latin America Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  91. Latin America Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  92. Latin America Eye Clinics Market, By Region, From 2021 to 2026 (USD Million)
  93. Latin America Diagnostic Centers Market, By Region, From 2021 to 2026 (USD Million)
  94. Latin America Patients Market, By Region, From 2021 to 2026 (USD Million)
  95. Brazil Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  96. Brazil Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  97. Argentina Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  98. Argentina Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  99. Mexico Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  100. Mexico Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  101. Middle East & Africa Ophthalmology Therapeutics Market, By Region, From 2021 to 2026 (USD Million)
  102. Middle East & Africa Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  103. Middle East & Africa Glaucoma Market, By Region, From 2021 to 2026 (USD Million)
  104. Middle East & Africa Dry Eye Syndrome Market, By Region, From 2021 to 2026 (USD Million)
  105. Middle East & Africa Diabetic Retinopathy Market, By Region, From 2021 to 2026 (USD Million)
  106. Middle East & Africa Retinal Vein Occlusion Market, By Region, From 2021 to 2026 (USD Million)
  107. Middle East & Africa Age-Related Macular Degeneration (AMD) Market, By Region, From 2021 to 2026 (USD Million)
  108. Middle East & Africa Macular Edema Market, By Region, From 2021 to 2026 (USD Million)
  109. Middle East & Africa Allergic Conjunctivitis Market, By Region, From 2021 to 2026 (USD Million)
  110. Middle East & Africa Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  111. Middle East & Africa Hospitals Market, By Region, From 2021 to 2026 (USD Million)
  112. Middle East & Africa Eye Clinics Market, By Region, From 2021 to 2026 (USD Million)
  113. Middle East & Africa Diagnostic Centers Market, By Region, From 2021 to 2026 (USD Million)
  114. Middle East & Africa Patients Market, By Region, From 2021 to 2026 (USD Million)
  115. Middle East Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  116. Middle East Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)
  117. Africa Ophthalmology Therapeutics Market, By Indication, From 2021 to 2026 (USD Million)
  118. Africa Ophthalmology Therapeutics Market, By End-User, From 2021 to 2026 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 4255

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample